cover letter
To: Cancer Research
George C. Prendergast, PhD, Editor-in-Chief
Re: xxxx et al. Manuscript on _____________.
Dear Editor(s),
Available for your review is our manuscript entitled “___________” submitted for publication in Cancer Research. The current manuscript describes for the first time______. Our results further indicate that _______.
All authors of this research paper have directly participated in the planning, execution, or analysis of the study. All authors of this paper have read and approved the final version submitted. The contents of this manuscript have not been copyrighted or published previously. The contents of this manuscript are not under consideration for publication elsewhere. The contents of this manuscript will not be copyrighted, submitted, or published elsewhere while acceptance by the manuscript is under consideration. There are no directly related manuscripts or abstracts, published or unpublished, by any author(s) of this paper.
We thank you for your time and consideration of this manuscript.
Sincerely,
XXXXX,MD
Dear editorial board of European Journal of Cardiology,
Please find enclosed the manuscript: “The angiotensin-converting enzyme is not a risk factor for myocardial infarction in French individuals”, by Sarah H., et al., to be submitted as a Short Communication to the European Journal of Neurology for consideration of publication. All co-authors have seen and agree with the contents of the manuscript and there is no financial interest to report. We certify that the submission is original work and is not under review at any other publication.
In this manuscript, we report the results of the first study on the genetic and functional roles of the ACE on the risk of suffering a myocardial infarction in the French population. Indeed, we genotyped the rs4341 polymorphism in 531 IS cases and 549 healthy controls, and then performed functional studies by measuring serum ACE protein level and activity in
George C. Prendergast, PhD, Editor-in-Chief
Re: xxxx et al. Manuscript on _____________.
Dear Editor(s),
Available for your review is our manuscript entitled “___________” submitted for publication in Cancer Research. The current manuscript describes for the first time______. Our results further indicate that _______.
All authors of this research paper have directly participated in the planning, execution, or analysis of the study. All authors of this paper have read and approved the final version submitted. The contents of this manuscript have not been copyrighted or published previously. The contents of this manuscript are not under consideration for publication elsewhere. The contents of this manuscript will not be copyrighted, submitted, or published elsewhere while acceptance by the manuscript is under consideration. There are no directly related manuscripts or abstracts, published or unpublished, by any author(s) of this paper.
We thank you for your time and consideration of this manuscript.
Sincerely,
XXXXX,MD
Dear editorial board of European Journal of Cardiology,
Please find enclosed the manuscript: “The angiotensin-converting enzyme is not a risk factor for myocardial infarction in French individuals”, by Sarah H., et al., to be submitted as a Short Communication to the European Journal of Neurology for consideration of publication. All co-authors have seen and agree with the contents of the manuscript and there is no financial interest to report. We certify that the submission is original work and is not under review at any other publication.
In this manuscript, we report the results of the first study on the genetic and functional roles of the ACE on the risk of suffering a myocardial infarction in the French population. Indeed, we genotyped the rs4341 polymorphism in 531 IS cases and 549 healthy controls, and then performed functional studies by measuring serum ACE protein level and activity in